A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
|Conatus Pharmaceuticals, Inc.
|Male and Female Patients
|U.S. Govt. ID:
|Cristina Falo PhD: 1 212 305 6758 / firstname.lastname@example.org
Patients who have been diagnosed with decompensated nonalcoholic steatohepatitis (NASH) cirrhosis may be eligible to participate in this clinical trial. NASH is liver inflammation and damage caused by a buildup of fat in the liver. The main purpose of the study is to test the safety and efficacy of a drug called Emricasan (IDN-6556) in reducing the risk of complications related to liver disease. Eligible patients will be randomized to receive 5 mg or 25 mg of emricasan, or placebo orally twice a day for at least 48 weeks (and potentially up to 2.5 years, depending on enrollment timeline).
This study is closed
Elizabeth Verna, MD
|Have you been diagnosed with cirrhosis?
|Have you been diagnosed with NASH or fatty liver disease?
|Have you had a liver transplant?
|Have you had cancer of the liver?
|Do you have HIV?